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A B S T R A C T
Purpose
Adjuvant carboplatin is one of three management strategies that may follow inguinal orchiectomy in
clinical stage I seminoma. However, little is known about the outcome of patients who experience
a relapse after such treatment.
Patients and Methods
Data from 185 patients who relapsed after adjuvant carboplatin between January 1987 and August
2013 at 31 centers/groups from 20 countries were collected and retrospectively analyzed. Primary
outcomes were disease-free survival and overall survival. Secondary outcomes were time to, stage
at, and treatment of relapse as well as rate of subsequent relapses.
Results
With a median follow-up of 53 months (95% CI, 48 to 60 months) the 5-year disease-free survival
was 82% (95% CI, 77% to 89%), and the 5-year overall survival was 98% (95% CI, 95% to 100%).
Themedian time from orchiectomy to relapsewas 19months (95%CI, 17 to 23months); 15% (95%
CI, 10% to 21%) of relapses occurred . 3 years after treatment. The majority of relapses were
detected by computed tomography scan during routine follow-up, 98% in the International Germ
Cell Cancer Collaborative Group good prognosis group. Chemotherapy was administered to 92% of
patients, mostly as standard ﬁrst-line treatment corresponding to stage; 8% of patients had additional
local treatments. Only 28 patients experienced a second relapse. At last follow-up, 174 (94%) of 185
patients were alive without disease, and four patients with disease. Seven patients died, three of
whom due to progressive disease.
Conclusion
Within the limitations of a retrospective analysis, the results suggest that the majority of patients
who experience a relapse after adjuvant carboplatin for clinical stage I seminoma can be suc-
cessfully treated with a cisplatin-based chemotherapy regimen adequate for stage. Because 15%
of the relapses occurred . 3 years after adjuvant treatment, a minimum of 5 years follow-up is
recommended.
J Clin Oncol 35:194-200. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Approximately three quarters of patients with
pure seminoma of the testis present with clinical
stage I (CSI), deﬁned as disease limited to the
testis with normal serum tumor markers and no
evidence of local or distant metastases after in-
guinal orchiectomy.1,2 Three different manage-
ment strategies—active surveillance, adjuvant
para-aortic radiation, and adjuvant chemotherapy
with carboplatin—can be pursued after surgery.
Each strategy provides a similarly excellent 5-year
survival of approximately 98%, but they differ
in their relapse rate and their need for further
treatment.3
Relapses are observed among $ 20% of
patients who undergo active surveillance, partic-
ularly if risk factors for occultmetastatic disease are
present. Adjuvant treatment with either radio-
therapy or carboplatin can substantially reduce
this risk. In a large prospective randomized trial,
relapse rates and survival probabilities were similar
with adjuvant radiotherapy or carboplatin for CSI
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seminoma.4,5 However, because of the ease of administration,
quicker recovery from adverse effects of adjuvant treatment, and
the known long-term risks for induction of secondary malig-
nancies after adjuvant radiotherapy,6-8 adjuvant carboplatin has
been favored over adjuvant radiotherapy, which is no longer
recommended as a standard option.3,9 As a result of insufﬁcient
follow-up, no data are available yet with respect to long-term
toxicities and the potential induction of secondary malignancies
after adjuvant carboplatin.
After adjuvant carboplatin in CSI seminoma, a relapse rate
of approximately 4% to 9% has been reported.4,5,10-12 The
timing and location as well as the treatments and respective out-
comes of such relapses have not been exclusively studied so far. In
particular, whether the prognosis of patients with relapse is com-
promised by previous adjuvant treatment remains unclear.
Because a prospective trial unlikely will ever be conducted in this
patient population, we retrospectively collected data from 31
centers/groups worldwide to analyze time to and stage at relapse,
mode of detection, and the treatments patients received and
their respective outcomes.
PATIENTS AND METHODS
We contacted centers worldwide, mostly through the network of the
Global Germ-Cell Cancer Group, and explored whether they had treated
patients with CSI seminoma and a relapse after one or two cycles of
adjuvant carboplatin. Focus of the analysis was solely on patients with
unequivocal relapse after adjuvant carboplatin. After identiﬁcation of
suitable cases, detailed information on patients was collected through
predeﬁned structured questionnaires. The protocol for the analysis and
the case report forms are provided in the Data Supplement. Approval of
the local ethics committee was obtained before the retrospective data
collection.
Information was collected on patient characteristics at the time of
treatment with carboplatin; methods used for dosing of carboplatin; and
time to, detection of, and location of relapse. Data on imaging modalities,
elevation of tumor markers at time of relapse, and treatment of relapse
(surgery, radiotherapy, chemotherapy, or combination) as well as outcome
of this treatment were gathered. If applicable, data about further relapses
and treatment modalities of subsequent relapses were obtained as was the
cause of death, if applicable. Data were collected and anonymized locally
and subsequently transferred and entered into a joint database in St Gallen,
Switzerland.
Good prognosis
(n = 181; 98%)
Intermediate prognosis
(n = 4; 2%)
IGCCCG
Group in First
Relapse
Assessed for eligibility
(N = 203)
Included in data analysis
(n = 185)
Alive
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Death
(n= 4; 2%)
Alive without
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a result of PD
(n = 1; 0.5%)
Other
cause
(n = 2; 1%)
As a result
of PD
(n = 2; 1%)
With
disease
(n = 4; 2%)
Without
disease
(n = 19; 10%)
Excluded
  Lack of relevant data
  Contralateral second
     tumor present
(n = 18)
  (n = 9)
  (n = 9)
No further
relapse
(n = 154; 83%)
Further
relapse
(n = 27; 15%)
No further
relapse
(n = 3; 1.5%)
Further relapse
(n = 1; 0.5%)
Alive without
disease
(n = 152; 82%)
Death
other
(n = 2; 1%)
Fig 1. Overview of patients. IGCCCG, International
Germ Cell Cancer Collaborative Group; PD, pro-
gressive disease.
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Patients
Inclusion criteria were male sex, age 18 years and older, pure semi-
noma at initial histology, CSI, and normal value of the tumor marker
alpha-fetoprotein at initial diagnosis. Further conditions for inclusionwere
orchiectomy for seminoma, one or two cycles of adjuvant carboplatin, and
clinical or radiologic conﬁrmation of recurrent seminoma.
Exclusion criteria were other malignancies that required cytotoxic
therapy during the time of follow-up, nonseminoma histology or any other
histology apart from pure seminoma at initial diagnosis, treatment with
more than two cycles of adjuvant carboplatin, and elevated levels of alpha-
fetoprotein at initial diagnosis. Disease stage was reported according to the
International Union Against Cancer classiﬁcation,13 and for allocation to
risk categories, the International Germ Cell Cancer Collaborative Group
(IGCCCG) prognostic classiﬁcation14 was used.
Statistical Analysis
Data of 185 patients who had received adjuvant treatment with
carboplatin between January 1987 and August 2013 in 31 centers/groups
from 20 countries and who had experienced a relapse were retrospectively
analyzed. Primary end points were overall survival (OS) and disease-free
survival (DFS). Secondary outcomes were time to relapse, stage at relapse,
management strategies chosen, and rates of subsequent relapses. Time-to-
event end points were analyzed by the Kaplan-Meier method. Calculation
of time to relapse started with the date of orchiectomy. Calculation of time
to subsequent relapse started with the date of diagnosis of the ﬁrst relapse.
DFS and OS started with day 1 of treatment at ﬁrst relapse; DFS ended with
progression of disease or death of any cause; OS ended with death.
Censoring was done at the date of last contact. For ﬁve patients, the exact
date of initiation of treatment of relapse was missing. For these patients,
date of relapse plus 20 days (median difference in patients with both dates
available) was taken as the starting date.
RESULTS
Overall, information on 203 patients with CSI seminoma with
relapses after adjuvant carboplatin was collected. Data from nine
patients were excluded because of lack of important information
(eg, time of relapse, treatment modality used as treatment of re-
lapse). Nine additional patients were excluded because at the time
of suspected relapse a contralateral seminoma had been diagnosed.
In these latter patients, a clear distinction between metastases
from the contralateral cancer versus a true relapse from the in-
cident primary tumor could not be made. In summary, 185 pa-
tients with a median follow-up of 53 months (95% CI, 48 to
60 months) were considered eligible and included in the analysis.
Figure 1 shows an overview of the patient cohorts and their
respective outcomes. The median time to relapse was 19 months
(95%CI, 17 to 23months); 118 (64%; 95%CI, 56% to 71%) of 185
relapses occurred during the ﬁrst 2 years after adjuvant treatment.
However, 39 (21%; 95%CI, 15% to 28%) relapses occurred between
2 and 3 years, and 28 (15%; 95% CI, 10% to 21%) were reported
after 3 years. The earliest relapse was documented 4 months after
orchiectomy, the latest relapse occurred after 15 years.
Mode of Detection, Relapse Pattern, and Treatments
After Adjuvant Carboplatin
Table 1 lists the characteristics of patients at the time of relapse
after adjuvant carboplatin. Relapses were detected by routine
follow-up in 137 (79%) of 173 patients for whom this information
was available; in only 36 (21%) patients, detection of relapse was
triggered by suspicion as judged by the treating physicians. Of 184
patients, relapses ﬁrst became evident by computed tomography
scan or magnetic resonance imaging in 117 (64%), by clinical signs
or symptoms in 28 (15%), and by increasing levels of lactate
dehydrogenase or human chorionic gonadotropin in 23 (13%).
Positron emission tomography scan or other imaging modalities
(eg, x-ray, ultrasound) were infrequently used and provided the
ﬁrst evidence of relapse in only ﬁve (3%) and 11 (6%) patients,
respectively. In one patient, no mode of initial detection of relapse
was documented.
Of 182 patients, stage at relapse was IIB in 88 (48%), IIA in 35
(19%), and IIC in 31 (17%). Only 28 (15%) patients presented
with stage III disease. No stage was documented in the remaining
three patients. Location and frequency of metastases are listed in
Appendix Table A1 (online only).
Table 1. Characteristics at Baseline, Relapse, and Current Status
Characteristic Proportion (%)
Median age (range), years 38 (19-68)
Method used for carboplatin dosing
Radionuclides 78 of 150 (52)
24-h urine collection 12 of 150 (8)
Serum creatinine–based approximation 60 of 150 (40)
Unknown 35
Cycles of adjuvant carboplatin
One 147 of 183 (80)
Two 36 of 183 (20)
Unknown 2
Time to relapse
Median months (range) 19 (4-184)
During year 1 41 of 185 (22)
During year 2 77 of 185 (42)
During year 3 39 of 185 (21)
After year 3 28 of 185 (15)
First evidence of relapse
Clinical symptoms/signs 28 of 184 (15)
Markers 23 of 184 (13)
CT scan/MRI 117 of 184 (64)
PET scan 5 of 184 (3)
X-ray/ultrasound 11 of 184 (6)
Unknown 1
Stage at relapse
IIA 35 of 182 (19)
IIB 88 of 182 (48)
IIC 31 of 182 (17)
III 28 of 182 (15)
Unknown 3
IGCCCG prognostic group
Good 181 of 185 (98)
Intermediate 4 of 185 (2)
Second relapse
No 156 of 184 (85)
Yes 28 of 184 (15)
Unknown 1
Status at last follow-up, No.
Alive without disease 174
Alive with disease 4
Death, disease related 3
Death, probably therapy related 2*
Death, other cause 2†
Abbreviations: CT, computed tomography; IGCCCG, International Germ Cell
Cancer Collaborative Group; MRI, magnetic resonance imaging; PET, positron
emission tomography.
*One secondary leukemia, one treatment related not speciﬁed.
†One each myocardial infarction and chronic obstructive pulmonary disease.
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According to the IGCCCG classiﬁcation, all but four patients
had a relapse with good prognosis disease. The four patients with
intermediate prognosis disease relapsed 10, 24, 27, and 36 months
after orchiectomy. Details of these patients are listed in Appendix
Table A2 (online only). Three additional patients were considered
to have intermediate prognosis disease by their treating physicians
based on elevated lactate dehydrogenase levels but were reclassiﬁed
as good prognosis for the purpose of the present analysis because in
seminoma, the IGCCCG classiﬁcation uses nonpulmonary visceral
metastases as the sole criterion for intermediate prognosis.
Details of the treatments given at the time of relapse after
adjuvant carboplatin are shown in Figure 2. The majority of the
185 patients (156 [84%]) received chemotherapy alone; 14 (8%)
were treated with a combination of chemotherapy plus local
treatment (radiotherapy or surgery; Fig 2A). Local treatment
without chemotherapy was rarely used, wherein 11 (6%) patients
received radiotherapy alone and four (2%) underwent surgery as
their only treatment. Of the 156 patients who received chemo-
therapy alone, the regimen comprised three cycles of bleomycin,
etoposide, cisplatin (BEP) in 56 (36%) and four cycles of etoposide,
cisplatin (EP) in 52 (33%; Fig 2B). Four cycles of BEP were used in
16 (10%) patients (13 good prognosis, three intermediate prog-
nosis), and 32 (21%) patients were treated with other combinations/
schedules, which are listed in Appendix Table A3 (online only).
Overall, 28 (15%; 95% CI, 10% to 21%) of 185 patients
experienced a subsequent relapse. Of those, 27 had previously been
classiﬁed as IGCCCG good prognosis and only one as intermediate
prognosis (Fig 1). The median time from diagnosis of the ﬁrst
relapse to diagnosis of the second relapse was 9 months (95% CI,
7 to 16 months). Characteristics of treatment and outcome in
patients with subsequent relapses are listed in Table 2. More second
relapses, 10 (28%; 95% CI, 14% to 45%) of 36, were observed in
patients who had received two cycles of adjuvant carboplatin
compared with 18 (12%; 95% CI, 7% to 19%) of 146 in patients
who had received a single cycle of adjuvant carboplatin (P = .04,
Fisher exact test).
At the time of last follow-up, ﬁve of the patients with a second
relapse died, three as a result of progressing seminoma, and two as
a result of other causes. Four patients were alive with disease, and
19 were alive without disease.
Survival
At the time of last follow-up, 174 (94%; 95% CI, 90% to 97%)
of 185 patients were alive without evidence of disease; four (2%)
were reported to be alive with persisting disease. Seven (3%) patients
died, three as a result of progressing seminoma and two as a result
of possible treatment-related causes (one secondary leukemia, one
treatment related without further speciﬁcation). Two patients died
as a result of other causes as assessed by their local physicians (one
myocardial infarction, one chronic obstructive pulmonary dis-
ease). However, a relationship between these two latter deaths and
treatment of seminoma cannot be ruled out. Details on the patients
who died as a result of other causes are listed in Appendix Table A4
(online only). Figure 3A shows the DFS and OS probabilities after
treatment of relapse for all patients. The 5-year DFS was 82% (95%
CI, 77% to 89%), and the 5-year OS was 98% (95% CI, 95%
to 100%) in the entire cohort of 185 patients. In the subgroup of
111 (60%) patients who received only standard chemotherapy
according to their stage and prognostic IGCCCG group, outcomes
were similar, with a 5-year DFS of 82% (95% CI, 74% to 91%) and
a 5-year OS of 97% (95% CI, 93% to 100%; Fig 3B). Standard
chemotherapy treatment of patients with IGCCCG good prognosis
was deﬁned as three cycles of BEPor four cycles of EP (n = 108) and
for patients with IGCCCG intermediate prognosis as four cycles of
BEP (n = 3).
A trend for a worse DFS (hazard ratio, 2.0; 95% CI, 0.9 to 4.4;
P = .07) was observed in patients who had received two cycles of
A
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Fig 2. Treatment of ﬁrst relapse. (A) Treatment modality used in ﬁrst relapse. (B) Type of chemotherapy chosen for patients treated only with chemotherapy in ﬁrst
relapse. (*) Other schedules used are listed in detail in Appendix Table A3 (online only). BEP 3 3, three cycles of bleomycin, etoposide, cisplatin; BEP 3 4, four cycles of
bleomycin, etoposide, cisplatin; EP 3 4, four cycles of etoposide, cisplatin; RT, radiotherapy.
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adjuvant carboplatin, but no difference in OS was seen (data not
shown). In addition, we observed a statistically nonsigniﬁcant
negative trend for an inferior DFS in patients who experienced
a relapse , 12 months after orchiectomy and adjuvant treatment
(hazard ratio, 1.9; 95% CI, 0.9 to 4.1). However, too few events
were observed to draw conclusions with respect to time of relapse
and correlation with OS.
DISCUSSION
In this large retrospective analysis in 185 patients who had a relapse
after one or two cycles of adjuvant carboplatin for CSI seminoma,
we found that such patients still have excellent survival proba-
bilities, similar to patients with de novo metastatic disease. With
a median follow-up of 53 months, we found a 5-year DFS of 82%
and a 5-year OS of 98%. Only three patients died as a result of
progressive seminoma, and two patients died as a result of possible
treatment-related causes. For two other patients reported to have
died as a result of other causes by their treating physicians, a relation
to seminoma treatment could not be ruled out with certainty. These
results correspond favorably to the IGCCCG population. In the
IGCCCG data set,14 patients with de novo metastatic seminoma in
the good prognosis group had a 5-year DFS probability of 82% and
a 5-year OS probability of only 86%. Even compared with more
modern patient series in metastatic seminoma with a better 5-year
OS of approximately 95%,15-17 the outcomes found in the current
series of patients pretreated with adjuvant carboplatin are still
similar. These results demonstrate for the ﬁrst time to our knowledge
that in CSI seminoma, survival probabilities are not impaired after
adjuvant carboplatin, even in patients who relapse despite such
treatment.
Of note, more relapses occurred in patients who received
two cycles of carboplatin. This result should be interpreted with
caution because of the retrospective nature of the study, potential
biases, and the small number of patients and events. Still, these data
do not seem to support the use of two cycles of carboplatin in the
adjuvant setting.
Table 2. Characteristics, Treatment, and Outcome of Patients With Subsequent Relapse
IGCCCG
Group Stage
Elevated
Markers
DFI
(months)
Therapy in First Relapse
(No. of cycles)
Best
Response Therapy in Second Relapse Status at Last Follow-Up
Intermediate III Yes 10 BEP 3 4 PR m+ TIP 3 3 Death as a result of PD
Good III Yes 27 BEP 3 3* PR m2 Chemotherapy not speciﬁed Alive with disease
Good III Yes 162 EP 3 4 PR m2 TIP 3 4 Death as a result of PD
Good IIA Yes 8 BEP 3 3 CR Radiation only Alive without disease
Good IIC No 63 EP 3 4 CR TIP 3 4 and radiation Alive without disease
Good NA Yes 15 EP 3 4 CR VIP 3 4 Alive without disease
Good III No 134 BEP 3 4 SD NA (treatment in other institution) Alive without disease
Good IIB No 5 EP 3 4 PR m2 VIP 3 2 Alive without disease
Good IIC Yes 8 BEP 3 3 PR m2 TIP 3 3 and surgery Alive without disease
Good III No 14 BEP 3 3 PR m2 Radiation only Further relapse, afterward alive
without disease
Good IIB No 12 Radiation only CR EP 3 3 + one cycle etoposide +
carboplatin
Death of myocardial infarction
Good IIC Yes 13 BEP 3 4 PR m2 TIP 3 4 and radiation Alive without disease
Good IIC Yes 107 BEP 3 4 PR m2 TIP 3 4 Alive without disease
Good IIB No 6 EP 3 4 CR Radiation and surgery Further relapse, afterward alive
without disease
Good IIC Yes 30 BEP 3 3 CR Surgery only Further relapse, afterward alive
without disease
Good IIC Yes 11 BEP 3 3 PR m+ High-dose chemotherapy Further relapse, alive with
disease
Good IIB No 12 BEP 3 4 and surgery CR Radiation only Further relapse, alive with
disease
Good IIB No 4 BEP 3 3 CR Surgery only Further relapse, afterward alive
without disease
Good IIB No 8 EP 3 4 CR TIP 3 3 and surgery Alive without disease
Good IIB Yes 24 Radiation only CR EP 3 4 Alive without disease
Good IIC Yes 29 BEP 3 3, CEB 3 1 PR m2 TIP 3 4 and radiation Alive without disease
Good IIB No 12 BEP 3 3 CR VIP 3 2 and radiation Alive without disease
Good IIB No 7 BEP 3 3 CR TIP 3 4 Alive without disease
Good III Yes 18 BEP 3 3, EP 3 1 CR Oral etoposide, VIP, high dose Death as a result of secondary
leukemia
Good IIC Yes 22 BEP 3 3, EP 3 1 PR m2 Oxaliplatin, actinomycin, high-dose
methotrexate, paclitaxel 3 4
Alive without disease
Good IIC Yes 12 BEP 3 4 and surgery CR VIP 3 4 Further relapse, alive with
disease
Good IIB No 15 BEP 3 3 PR m2 High-dose chemotherapy Further relapse, death as
a result of PD
Good IIB No 9 BEP 3 4 and surgery CR TIP 3 4 and surgery Alive without disease
Abbreviations: BEP, bleomycin, etoposide, cisplatin; CEB, carboplatin, etoposide, bleomycin, CR, complete remission; DFI, disease-free interval between adjuvant
carboplatin andmanifestation of ﬁrst relapse; EP, etoposide, cisplatin;m2, negativemarker;m+, positivemarker; NA, not applicable; PD, progressive disease; PR, partial
remission; SD, stable disease; TIP, paclitaxel, ifosfamide, cisplatin; VIP, etoposide, ifosfamide, cisplatin.
*Intended cycle 4 not administered because of the patient’s wish as a result of complications; bleomycin not fully dosed in cycle 3.
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In the absence of a prospective randomized trial, the optimal
treatment of relapses after adjuvant carboplatin remains unknown.
However, in this series, conventional dose chemotherapy with
either EP or BEP, which would have been adequate standard
treatment of patients with de novo metastatic disease, was used in
the majority of patients who relapsed. In the remaining patients,
either a combination of chemotherapy plus local surgery (n = 11)
or radiation (n = 3), local radiation alone (n = 11), or surgery alone
(n = 4) had been applied. On the basis of this information, we
suggest that patients who relapse after adjuvant carboplatin should
be treated identically to patients with de-novo metastatic disease.
The median time to ﬁrst relapse after adjuvant carboplatin
was 19 months in this series. In accordance with previous reports,16
the majority of ﬁrst relapses occurred in the retroperitoneum and were
detected by computed tomography scan or magnetic resonance imaging
during routine follow-up. Self-reported symptoms, clinical signs, or
elevated tumor markers were noticed as the ﬁrst evidence of relapse in
only aminority of patients. Of note, more than one third of patients had
a relapse beyond a follow-up period of 2 years, and 15% relapsed beyond
a follow-up period of 3 years. This ﬁnding suggests that compared with
active surveillance, adjuvant treatment with carboplatin may delay re-
lapses. Kollmannsberger et al15 studied active surveillance in CSI
seminoma and reported a median time to relapse of 14 months, with
only 8% relapses occurring beyond 3 years. A prospective population-
based study by Tandstad et al17 used a risk-adapted approach. Patients
managed by active surveillance had amedian time to relapse of 1.3 years,
and 17% of the relapses occurred . 2 years after orchiectomy. Patients
managed with adjuvant carboplatin had a median time to relapse of 1.7
years, and 33% of the relapses occurred . 2 years after orchi-
ectomy. In the largest published series by Mortensen et al,16 the
median time to relapse in 1,954 patients with CSI seminoma treated
with active surveillance was 13.7 months, but 22% of relapses oc-
curred between 3 and 5 years and 4% . 5 years after orchiectomy.
Similar results were reported by the German Testicular Cancer
Group.10 Taken together, these data indicate that although adjuvant
carboplatin will reduce the risk of relapse in CSI seminoma com-
pared with active surveillance, prolonged follow-up beyond 3 years
may be required in patients after adjuvant treatment.18
In the present series, 28 (15%) of 185 patients treated for their ﬁrst
relapse after adjuvant carboplatin experienced a second relapse. This rate
is similar to a 14% second relapse rate from a retrospective analysis of
patients treated with adjuvant carboplatin in south central England,
which is included in the present series,11 and similar to patients treated
for de novometastatic seminoma. Surveillance studies, however, reported
lower second relapse rates. Kollmannsberger et al15 reported a 4% second
relapse rate in CSI seminoma after initial active surveillance and sub-
sequent cisplatin-based ﬁrst-line chemotherapy with a similar median
follow-upof 52months comparedwith the current series. In the study by
Mortensen et al,16 only eight (6%) of 136 patients who experienced
a relapse during active surveillance and received treatment with BEP had
a second relapse. Similarly, the Swedish andNorwegian Testicular Cancer
Group19 observed only one second relapse among 65 patients with CSI
seminoma who underwent active surveillance as initial management.
This higher rate of subsequent relapses and the more-frequent need
for further salvage treatment needs to be studied further.
Patient selection and different patient populations at ﬁrst
relapse might explain these discrepancies. First, adjuvant carbo-
platin is primarily used in patients with one or more risk factors,
which reﬂects more-advanced and/or more-aggressive disease.17,20
Second, because we analyzed only patients who relapsed after
carboplatin treatment, this series might have selected patients with
biologically more unfavorable disease as a result of carboplatin
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Fig 3. Overall survival (OS) and disease-free survival (DFS) for all patients and for patients who received standard therapy for their stage and prognostic category at ﬁrst
relapse. (A) DFS and OS for all patients. (B) DFS and OS for patients with good prognosis treated with three cycles of bleomycin, etoposide, cisplatin or four cycles of
etoposide, cisplatin and patients with intermediate prognosis treated with four cycles of bleomycin, etoposide, cisplatin or four cycles of etoposide, ifosfamide, cisplatin.
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resistance. However, it is conceivable that adjuvant carboplatin may
induce some form of cisplatin resistance and may reduce subsequent
activity of this drug if further chemotherapy is needed. Second
relapses in this series, however, could successfully be salvaged with
further treatment in the majority of patients.
In conclusion, this study has all the limitations of a retrospective
analysis. Most importantly, because we studied only patients with
relapses after adjuvant carboplatin, we cannot comment on the entire
population of patients with CSI seminoma from whom the current
study sample was drawn.We also cannot comment on the overall risks
and beneﬁts of adjuvant carboplatin versus active surveillance. How-
ever, for the ﬁrst time in our knowledge, we demonstrate that adjuvant
carboplatin is safe, even in patients who experience a relapse after such
treatment. The majority of patients with CSI seminoma who expe-
rienced a relapse after adjuvant carboplatin could successfully undergo
salvage therapy with excellent survival probabilities by using the
treatment algorithms established for de novo metastatic disease.
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Appendix
Table A1. Frequency and Distribution of Metastases in First Relapse
No. of Patients
Presence of lymph node metastases*
Retroperitoneal 166
Paratracheal/mediastinal 16
Inguinal 10
Supraclavicular 3
Axillary 2
Retrocrural 2
Cervical 1
Presence of visceral metastases*
Lung 4
Liver 3
Bone 1
Occurrence of multiple metastases in one patient
Lymph nodes and visceral 6
Lung and lymph nodes 3
Liver and lymph nodes 2
Lung, liver, and lymph nodes 1
Lymph nodes and soft tissue/muscle 1
Multiple lymph node locations 14
Lymph nodes, retroperitoneal and mediastinal 7
Lymph nodes, retroperitoneal and other 6
Lymph nodes, retroperitoneal, mediastinal, and other 1
*Multiple locations possible.
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Table A2. Characteristics at Baseline, Treatment and Outcome of Patients With IGCCCG Intermediate Prognosis
IGCCCG
Age
(years)
Cycles of
Carboplatin
Dosing
Method
Localization of
Metastases
b-HCG
Elevated
LDH
Elevated
Treatment
(No. of
cycles)
Subsequent
Relapse
Treatment
(No. of
cycles)
Last
Status
Intermediate 44 1 Cockcroft
Gault
Bone No Yes BEP 3 3
VIP 3 1
No NA Alive w/o
Intermediate 48 1 Radionuclides LN retroperitoneal,
mediastinal, axillary, liver
Yes Yes BEP 3 4 No NA Alive w/o
Intermediate 25 1 Wright
formula
LN mediastinal, lung, liver Yes No BEP 3 4 No NA Alive w/o
Intermediate 24 2 Cockcroft
Gault
LN neck, liver Yes Yes BEP 3 4 Yes TIP 3 3 Death as
a result of PD
Abbreviations: BEP, bleomycin, etoposide, cisplatin; b-HCG, b-human chorionic gonadotropin; IGCCCG, International Germ Cell Cancer Collaborative Group; LDH,
lactate dehydrogenase; LN, lymph node; NA, not applicable; PD, progressive disease; TIP, paclitaxel, ifosfamide, cisplatin; VIP, etoposide, ifosfamide, cisplatin; w/o,
without disease.
Table A3. Other Types/Schedules of Therapy Chosen for Treatment of First
Relapse
Therapy (No. of cycles) No. of Patients
Chemotherapy only
EP 3 3 16
BEP (cycles unknown) 1
I-BEP 3 3 1
BEP 3 3 + VIP 3 1 1
BEP 3 2 + EP 3 2 2
BEP 3 3 + EP 3 1 5
BEP 3 2 + EP 31 1
BEP 3 1 + EP 3 3 2
EP 3 3 + etoposide/carboplatin AUC 7 3 1 1
BEP 3 3 + CEB 3 1 1
VIP 3 4 1
Chemotherapy and local treatment
BEP 3 3 + RT 1
EP 3 1 + RT 1
Carboplatin AUC 7 3 2 + RT 1
BEP 3 4 + surgery 3
BEP 3 3 + surgery 2
BEP 3 2 + surgery 1
EP 3 4 + surgery 3
VIP 3 3 + surgery 1
VIP 3 2, EP 3 4 + surgery 1
Abbreviations: AUC, area under the curve; BEP, bleomycin, etoposide, cisplatin;
CEB, carboplatin, etoposide, bleomycin; EP, etoposide, cisplatin; I-BEP, ifosfa-
mide, bleomycin, etoposide, cisplatin; RT, radiotherapy; VIP, etoposide, ifosfa-
mide, cisplatin.
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Table A4. Characteristics of Patients Who Died as a Result of Other Causes
Patient
Age at Adjuvant
Carboplatin (years)
Time to
Relapse
(months)
Treatment of
Relapse
(No. of cycles)
Subsequent
Relapse
Treatment
(No. of cycles)
Best
Response
Approximate Time From End of
Treatment to Death (years)
Death as a result
of MI
58 12 Radiation only Yes EP3 3 + carboplatin3 1,
etoposide
CR 7
Death as a result
of COPD
64 23 BEP 3 1, EP 3 3 No NA CR 14
Abbreviations: BEP, bleomycin, etoposide, cisplatin; COPD, chronic obstructive pulmonary disease; CR, complete remission; EP, etoposide, cisplatin; MI, myocardial
infarction; NA, not applicable.
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